MALCOLM DUNCAN: Open Payments
NPI 1033691746 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,062 in 127 payments from 10 companies in 2025. Trend: 2023 $5,535 · 2024 $17,329 · 2025 $8,062
Speaker / faculty: $4,308Food & beverage: $3,269Travel & lodging: $250Consulting: $155Education: $80
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 62 | $6,135 |
| Alkermes, Inc. | 24 | $759 |
| Neurocrine BioSciences, Inc. | 17 | $401 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $263 |
| E.R. Squibb & Sons, L.L.C. | 8 | $247 |
| Janssen Pharmaceuticals, Inc | 5 | $134 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Alpha Cognition USA, Inc. | 1 | $36 |
| ABBVIE INC. | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
Products named: AUSTEDO XR, UZEDY, ARISTADA, INGREZZA, CAPLYTA, COBENFY, INVEGA SUSTENNA, LYBALVI.
Industry payments across TX — which companies pay providers there.
